Research programme : anti-fibrotic therapeutics - ProMetic Life SciencesAlternative Names: PBI-4425; PBI-4547
Latest Information Update: 22 Jul 2016
At a glance
- Originator ProMetic Life Sciences
- Class Small molecules
- Mechanism of Action Cell differentiation modulators; Colony stimulating factor stimulants; Cytokine modulators; Erythropoiesis stimulants; Extracellular matrix protein inhibitors; Immunomodulators; Inflammation mediator modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic neuropathies; Hepatic fibrosis; Idiopathic pulmonary fibrosis